-

07:50:55 AM

STOK Stock News

STOK - Stoke Therapeutics Inc

03/15/23 7:00 AM

Nasdaq : STOK

clinical triallow float

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that the FDA will allow the administration of a higher single dose of STK-001 in its ongoing Phase 1/ 2 a MONARCH study of children and adolescents with Dravet...

RHEA-AI

neutral

03/06/23 7:00 AM

Nasdaq : STOK

earningslow float

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates. “In 2022 we continued to advance the first potential new medicine to treat...

RHEA-AI

neutral

02/27/23 4:30 PM

Nasdaq : STOK

conferenceslow float

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will be participating at the following upcoming investor conferences:. Cowen 43rd Annual Health Care Conference Date: Monday, March 6, 2023 Time:...

RHEA-AI

neutral

02/07/23 8:00 AM

Nasdaq : STOK

conferenceslow float

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 4:20 p.m. ET. Stoke Therapeutics, is a...

RHEA-AI

neutral

01/09/23 8:00 AM

Nasdaq : STOK

low float

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today outlined its expected milestones and the following strategic priorities for 2023:. “Our recent data showed the first evidence that upregulating protein expression with...

RHEA-AI

neutral

01/04/23 9:00 AM

Nasdaq : EXEL, STOK

management

Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer

Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer and member of the Board of Directors. Ms. Smith has over 20 years of experience in the life science industry, with a focus on leading private...

RHEA-AI

neutral

01/04/23 8:00 AM

Nasdaq : STOK

conferenceslow float

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 2:15 p.m. ET. About Stoke Therapeutics Stoke...

RHEA-AI

neutral

12/02/22 9:00 AM

Nasdaq : STOK

clinical triallow float

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet...

RHEA-AI

neutral

11/29/22 7:30 AM

Nasdaq : STOK

conferenceslow float

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the Company’ s work in Dravet syndrome have been accepted for presentation at the American Epilepsy Society 2022 Annual Meeting,...

RHEA-AI

neutral

11/14/22 7:00 AM

Nasdaq : STOK

earningslow float

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/ 2 a...

RHEA-AI

neutral

STOK Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.stoketherapeutics.com
CeoEdward Kaye
Security nameStoke Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees102
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address3 Preston Ct
StateMassachusetts
CityBedford
Zip01730-2379
CountryUS
Phone17814308200

About Stoke Therapeutics Inc

Stoke Therapeutics, is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company's belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.